BACKGROUND: Glaucoma is a sight-threatening disease affecting 3% of the population over the age of 50. Glaucoma is treatable, and severe vision loss can usually be prevented if diagnosis is made at an early stage. Genetic factors play a major role in the pathogenesis of the condition, and therefore, genetic testing to identify asymptomatic at-risk individuals is a promising strategy to reduce the prevalence of glaucoma blindness. Furthermore, unravelling genetic risk factors for glaucoma would also allow a better understanding of the pathogenesis of the condition and the development of new treatments. DESIGN: The Australian and New Zealand Registry of Advanced Glaucoma is a prospective study that aims to develop a large cohort of glaucoma cases with severe visual field loss to identify novel genetic risk factors for glaucoma blindness. METHODS: Clinical information and blood are collected from participants after referral by eye practitioners. Samples are collected across Australia and New Zealand using postage kits. PARTICIPANTS: Our registry has recruited just over 2000 participants with advanced glaucoma, as well as secondary and developmental glaucomas. RESULTS: A positive family history of glaucoma is present in more than half of the advanced glaucoma cases and the age at diagnosis is significantly younger for participants with affected relatives, which reinforces the involvement of genetic factors in glaucoma. CONCLUSIONS: With the collection of glaucoma cases recruited so far, our registry aims to identify novel glaucoma genetic risk factors to establish risk profiling of the population and protocols for genetic testing.
BACKGROUND:Glaucoma is a sight-threatening disease affecting 3% of the population over the age of 50. Glaucoma is treatable, and severe vision loss can usually be prevented if diagnosis is made at an early stage. Genetic factors play a major role in the pathogenesis of the condition, and therefore, genetic testing to identify asymptomatic at-risk individuals is a promising strategy to reduce the prevalence of glaucoma blindness. Furthermore, unravelling genetic risk factors for glaucoma would also allow a better understanding of the pathogenesis of the condition and the development of new treatments. DESIGN: The Australian and New Zealand Registry of Advanced Glaucoma is a prospective study that aims to develop a large cohort of glaucoma cases with severe visual field loss to identify novel genetic risk factors for glaucoma blindness. METHODS: Clinical information and blood are collected from participants after referral by eye practitioners. Samples are collected across Australia and New Zealand using postage kits. PARTICIPANTS: Our registry has recruited just over 2000 participants with advanced glaucoma, as well as secondary and developmental glaucomas. RESULTS: A positive family history of glaucoma is present in more than half of the advanced glaucoma cases and the age at diagnosis is significantly younger for participants with affected relatives, which reinforces the involvement of genetic factors in glaucoma. CONCLUSIONS: With the collection of glaucoma cases recruited so far, our registry aims to identify novel glaucoma genetic risk factors to establish risk profiling of the population and protocols for genetic testing.
Authors: Xikun Han; Emmanuelle Souzeau; Jue-Sheng Ong; Jiyuan An; Owen M Siggs; Kathryn P Burdon; Stephen Best; Ivan Goldberg; Paul R Healey; Stuart L Graham; Jonathan B Ruddle; Richard A Mills; John Landers; Anna Galanopoulos; Andrew J R White; Robert Casson; David A Mackey; Alex W Hewitt; Puya Gharahkhani; Jamie E Craig; Stuart MacGregor Journal: JAMA Ophthalmol Date: 2019-01-01 Impact factor: 7.389
Authors: Yi Lu; Veronique Vitart; Kathryn P Burdon; Chiea Chuen Khor; Yelena Bykhovskaya; Alireza Mirshahi; Alex W Hewitt; Demelza Koehn; Pirro G Hysi; Wishal D Ramdas; Tanja Zeller; Eranga N Vithana; Belinda K Cornes; Wan-Ting Tay; E Shyong Tai; Ching-Yu Cheng; Jianjun Liu; Jia-Nee Foo; Seang Mei Saw; Gudmar Thorleifsson; Kari Stefansson; David P Dimasi; Richard A Mills; Jenny Mountain; Wei Ang; René Hoehn; Virginie J M Verhoeven; Franz Grus; Roger Wolfs; Raphaële Castagne; Karl J Lackner; Henriët Springelkamp; Jian Yang; Fridbert Jonasson; Dexter Y L Leung; Li J Chen; Clement C Y Tham; Igor Rudan; Zoran Vatavuk; Caroline Hayward; Jane Gibson; Angela J Cree; Alex MacLeod; Sarah Ennis; Ozren Polasek; Harry Campbell; James F Wilson; Ananth C Viswanathan; Brian Fleck; Xiaohui Li; David Siscovick; Kent D Taylor; Jerome I Rotter; Seyhan Yazar; Megan Ulmer; Jun Li; Brian L Yaspan; Ayse B Ozel; Julia E Richards; Sayoko E Moroi; Jonathan L Haines; Jae H Kang; Louis R Pasquale; R Rand Allingham; Allison Ashley-Koch; Paul Mitchell; Jie Jin Wang; Alan F Wright; Craig Pennell; Timothy D Spector; Terri L Young; Caroline C W Klaver; Nicholas G Martin; Grant W Montgomery; Michael G Anderson; Tin Aung; Colin E Willoughby; Janey L Wiggs; Chi P Pang; Unnur Thorsteinsdottir; Andrew J Lotery; Christopher J Hammond; Cornelia M van Duijn; Michael A Hauser; Yaron S Rabinowitz; Norbert Pfeiffer; David A Mackey; Jamie E Craig; Stuart Macgregor; Tien Y Wong Journal: Nat Genet Date: 2013-01-06 Impact factor: 38.330
Authors: Puya Gharahkhani; Kathryn P Burdon; Alex W Hewitt; Matthew H Law; Emmanuelle Souzeau; Grant W Montgomery; Graham Radford-Smith; David A Mackey; Jamie E Craig; Stuart MacGregor Journal: Invest Ophthalmol Vis Sci Date: 2015-08 Impact factor: 4.799
Authors: Mona S Awadalla; John H Fingert; Benjamin E Roos; Simon Chen; Richard Holmes; Stuart L Graham; Mark Chehade; Anna Galanopolous; Bronwyn Ridge; Emmanuelle Souzeau; Tiger Zhou; Owen M Siggs; Alex W Hewitt; David A Mackey; Kathryn P Burdon; Jamie E Craig Journal: Am J Ophthalmol Date: 2014-10-02 Impact factor: 5.258
Authors: Thomas K Young; Emmanuelle Souzeau; Lance Liu; Lisa S Kearns; Kathryn P Burdon; Jamie E Craig; Jonathan B Ruddle Journal: Mol Vis Date: 2012-12-28 Impact factor: 2.367
Authors: Kathryn P Burdon; Paul Mitchell; Anne Lee; Paul R Healey; Andrew J R White; Elena Rochtchina; Peter B M Thomas; Jie Jin Wang; Jamie E Craig Journal: Am J Ophthalmol Date: 2014-09-19 Impact factor: 5.258